Abstract: Phosphodiesterase 2A (PDE2A) is highly and specifically expressed in particular brain regions that are affected by neurological disorders and in certain tumors. Development of a specific PDE2A radioligand would enable molecular imaging of the PDE2A protein via positron emission tomography (PET). Herein we report on the syntheses of three novel fluoroalkylated triazine derivatives (TA2-4) and on the evaluation of their effect on the enzymatic activity of human PDE2A. 
Introduction
Phosphodiesterases (PDEs) are a class of intracellular enzymes consisting of 11 families and 21 isoforms [1] [2] [3] [4] . The PDE family subtypes differ in their three-dimensional structure, kinetic and regulatory properties, cellular expression, intracellular location, inhibitor sensitivities, substrate selectivity and distribution within the organism. Due to hydrolysis of the cyclic nucleotides, PDEs affect the second messenger signaling cascades of cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP) [1, 2] . Therefore, pharmacological inhibition of PDEs has the potential to enhance cyclic nucleotide signaling and can provide a strategy for the prevention or treatment of various diseases [2, [5] [6] [7] [8] .
Phosphodiesterase 2A (PDE2A) is a dual-substrate specific enzyme degrading both nucleotides cAMP and cGMP. The PDE2A protein is highly and specifically expressed in particular brain regions such as striatum, cortex, hippocampus, substantia nigra, amygdala, and in olfactory neurons [9] [10] [11] [12] .
The specific distribution of the PDE2A protein in brain indicates a modulation of important neuronal functions associated to learning and memory [13] [14] [15] . Inhibition of PDE2A activity in brain is suggested to improve neuronal plasticity and memory formation due to increased cGMP levels in active synapses [16, 17] . Hence, PDE2A inhibitors might be promising compounds regarding drug development for treatment of neurodegenerative disorders such as Alzheimer's disease (AD) [3, 12] . In addition, this enzyme is highly expressed in certain tumors such as malignant melanoma and mammary carcinoma [18, 19] , and it is assumed that PDE2A activity is related to highly proliferative processes [20, 21] .
The most common PDE2A inhibitors, shown in Figure 1 , are erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) [2, 16, 22, 23] and BAY 60-7550 [2, 16, 17, [24] [25] [26] [27] [28] . [2, 16, 17, [22] [23] [24] [25] [26] [27] [28] .
Besides further PDE2A inhibitors developed for treatment of neurological disorders [3, [29] [30] [31] [32] [33] [34] [35] , two PDE2A radioligands for molecular imaging of this protein in the brain via positron emission tomography (PET) have been reported to date (Figure 2 ). [3, 36, 37] .
The PET ligand [ 18 F]B-23 developed by Janssen [3, 36] is highly affine towards the PDE2A protein but also for PDE10A (IC50 hPDE2A = 1 nM; IC50 rPDE10A = 11 nM). In microPET imaging studies with rats the highest accumulation of [ 18 F]B-23 has been observed in the striatum, however, radio-metabolites have been detected in the brain (at 2 min p.i.: 4%; at 10 min p.i.: 10% of total activity). The distribution pattern of PDE2A and PDE10A is comparable: e.g., both proteins are highly expressed in the caudate nucleus [9] . Thus, the reported uptake in the striatum may be caused by binding of [ The goal of our work is the imaging of the PDE2A protein in brain via PET that may enable early diagnostics of related diseases. Furthermore, specific PDE2A radioligands may also be used for the pharmacological characterization and evaluation of novel PDE2A inhibitors as therapeutics. Herein, we present the development of three novel fluoroalkylated derivatives (TA2-4) as PDE2A ligands starting from a triazine lead compound (TA1) [38] (Figure 3 ). Out of this series of derivatives, the two most suitable PDE2A inhibitors were 18 F-radiolabelled and investigated regarding their (i) in vitro properties using rat brain slices; (ii) metabolic stability in mice; and (iii) in vivo imaging potential using small-animal PET in mice.
Results and Discussion

Synthesis and in Vitro Binding
The novel fluoroalkylated derivatives TA2-4 presented as PDE2A ligands were developed starting from the triazine lead compound TA1 [38] . The structure of TA1 (Figure 3 ) contains a fluorine atom on the benzene ring. In terms of a planned 18 F-radiolabelling, this position is not activated for a nucleophilic aromatic substitution of a leaving group by [ 18 F]fluoride due to the enhanced electron density [39] . Therefore, we favored the introduction of a second fluorine atom in the phenolic ether group enabling a nucleophilic 18 F-radiolabelling at the alkyl side chain. The five steps synthesis of the lead compound TA1 has already been reported [38] and was partly optimized in this study (Scheme 1). The first step relates to the coupling reaction between the substituted 2-chloropyridine and the 4-methylimidazole component to afford 1. By using triethylamine (TEA) as base in the presence of 4-(dimethylamino)pyridine (DMAP) as catalyst instead of potassium carbonate, and replacing N,N-dimethylformamide (DMF) by chloroform as solvent, 1 was obtained isomerically pure and with a 20% higher yield (93% vs. 71% [38] ). Notably, a synthesis of compound 1 [38] resulting in an inseparable 4:1 mixture of the imidazole regioisomers has also been published by Malamas et al. [40] . For the reduction of the nitro group to the corresponding amine, milder reaction conditions (e.g., temperature and pressure) were used, affording 2 in similar yields (79% vs. 81% [38] ). Afterwards, a diazotization was performed followed by an intramolecular cyclisation (azo coupling) to get the triazine basic structure 3. By washing the precipitate instead of recrystallization or column chromatography, 3 was obtained in comparable yields (96% vs. 93% [38] ). The bromination at the imidazole site has been reported for the corresponding 4-methoxy compound [38] . The 2-methoxy-bromo derivative 4 was obtained in similar yields according to the literature (73% vs. 76% [38] ). Finally, the Suzuki coupling with the 5-butoxy-2-fluorophenyl boronic acid was performed as previously reported [38] affording the lead compound TA1 in 81% yield.
The subsequent cleavage of the butoxy group by boron tribromide resulted in the phenol compound TA1a in 98% yield. Notably, the butoxy group was selectively cleaved while the 2-methoxy function remained stable, even in the presence of a large excess of boron tribromide (up to 10 eq.). The novel derivatives TA2, TA3 and TA4 were successfully synthesized in 54%, 75% and 99% yield, respectively, using the phenolic intermediate TA1a and appropriate fluoroalkyl halides (Scheme 1).
The novel fluoroalkylated derivatives TA2-4 were evaluated in an enzyme assay [38] to determine their inhibitory potencies for the human recombinant PDE2A and PDE10A proteins. The IC50 values obtained by this assay represent relative measures of the respective target affinity of the compounds. We have previously shown for a specific PDE10A radioligand that the target affinity is within the same order of magnitude as the inhibitory potency of the corresponding non-radioactive reference compound [41] .
As mentioned, only ligands with high affinity and selectivity are suitable for PET imaging of PDE2A due to the comparable distribution pattern of PDE2A and PDE10A in the brain [9] . Table 1 summarizes the IC50 values of the lead compound TA1 and the novel fluoroalkylated derivatives TA2-4 for the inhibition of human PDE2A and human PDE10A. Compared to the lead compound TA1 the affinity and selectivity of TA2 and TA3 are slightly lower. Besides its high potency, TA4 shows the highest selectivity of all tested fluoroalkylated derivatives. These findings can be explained by the recently reported binding-induced hydrophobic pocket (H-pocket) in the active center of the PDE2A protein [3, 42] . This mechanism suggests that hydrophobic interactions between the propylphenyl group of BAY 60-7550 and the H-pocket might be responsible for the high PDE2A selectivity of this compound [42] . Accordingly, the strength of hydrophobic interactions with the H-pocket may be related to the increased chain lengths within the novel derivatives TA2-4.
Thus, the ligand TA3 and the very promising derivative TA4 were selected as candidates for 18 F-radiolabelling. The corresponding tosylate precursors TA3a and TA4a, necessary for a one-step nucleophilic 18 F-radiolabelling strategy, were synthesized with yields of 60%-65% by reaction of propane-1,3-diyl bis(4-methyl-benzenesulfonate) or butane-1,4-diyl bis(4-methyl-benzenesulfonate) with the phenolic intermediate TA1a (see Scheme 1).
Radiochemistry, Lipophilicity and in Vitro Stability
The novel PDE2A radioligands [ Figure 4 , the highest labelling yields were achieved by using 1 mg of the corresponding tosylate precursor TA3a or TA4a. Accordingly, an increase of the amount of tosylate precursor TA3a resulted in an unexpected decrease of the labelling yield, which is more pronounced at the early time points. Independent of the amount of precursor TA3a, only a single A time-dependent increase of the labelling yields was observed, however, 73% Figure 5 ), purified using solid phase extraction on a pre-conditioned RP cartridge and eluted with absolute ethanol. The solvent was evaporated at 70 °C and the radioligands were formulated in sterile isotonic saline containing 10% of ethanol (v/v) for better solubility. Aliquots of the final products were spiked with the related non-radioactive reference compounds TA3 and TA4 to verify the identities of [ F]TA3 by semi-preparative HPLC (system A), purification by solid phase extraction and elution of the RP cartridge, the radioligand was formulated manually in sterile isotonic saline containing 10% of ethanol (v/v) as described above. Analytical HPLC (system B) of the final product spiked with the non-radioactive reference compound TA3 confirmed the identity of [ 18 F]TA3 (see Figure 5 ). The radioligand was obtained with a radiochemical purity higher than 99%, a radiochemical yield of 41.7% ± 6.3% (n = 3), and a specific activity of 142.6 ± 35.2 GBq/µmol (EOS; n = 3) in a total synthesis time of 75 min.
Compared to the manual procedure, there were no significant differences regarding the radiochemical yield of [ 
In Vitro Autoradiographic Studies in Rat Brain
In vitro autoradiographic studies were accomplished by incubating sagittal sections of rat brain with [ , which is consistent with the distribution pattern of PDE2A protein in rat brain [9, 11] . Therefore, we assume that the novel radioligands might be appropriate for in vitro imaging of PDE2A. Notably, a specific PDE2A-radioligand (e.g., 3 H-labelled) is not commercially available and in vitro autoradiographic images of the PDE2A distribution in brain have not been published yet. The conventional extraction procedure is very work-intensive, time-consuming and-most important-an absolute quantification of the real composition in the samples is not possible due to 65%-85% recovery of total activity. In order to understand the impact of polar radiometabolites on the recovery yields, we used [ ]fluoride and subsequent extraction was performed, applying the same protocol as for the in vivo metabolism studies, revealing that only 34% of the total activity could be recovered.
In Vivo
These findings indicate that the binding of polar radiometabolites, especially with an ionic character, to the denatured proteins is stronger than interactions of the proteins with the intact radioligand and thus, these radiometabolites are not completely extractable. Accordingly, the real percentage ratio of intact radioligand to its radiometabolites cannot be quantified by RP-HPLC based on samples obtained from an extraction procedure.
Therefore we used micellar HPLC (MLC), because this method allows the direct injection of plasma samples without deproteination. MLC was recently investigated by Nakao et al. [44] regarding their suitability for direct plasma metabolite analysis of PET radioligands. As eluent a mixture of an aqueous solution of sodium dodecyl sulphate (SDS), phosphate buffer and 1-propanol was used. According to the published procedure [44] , a gradient mode was applied starting under micellar conditions to completely elute the protein fraction and release the protein bound 18 F-compounds by the SDS micelles. Subsequent increase of the amount of 1-propanol as organic modifier leads to high submicellar conditions [44, 45] resulting in the elution of the intact radioligand and its radio-metabolites.
Analysis of the MLC chromatograms revealed that only 5% of total activity in plasma are represented by intact radioligand [ Figure 7 ). Therefore we conclude that only MLC provides the detection of 100% of the real composition in the analyzed samples due to direct injection into the micellar HPLC system. 
PET/MR Studies of [
F]TA3 in Mice
The metabolism studies indicated that the metabolic stability of [ F]TA3 in anaesthetized CD-1 mice, the radioligand was injected intravenously (9.7 ± 1.3 MBq, SAEOS ~70 GBq/µmol, n = 4), and whole body scans were performed for 60 min in listmode with a Mediso nanoScan PET/MR scanner followed by dynamic reconstruction. Time-activity curves (TACs) were generated for regions of interest such as whole brain, striatum, and cerebellum ( Figure 8 ). As presented in Figure 8 , the TACs between 0 and 55 min p.i. show a fast wash out of activity from the striatum while a constantly increased uptake in the cerebellum was observed. This finding is not consistent with the distribution of PDE2A protein in murine brain which corresponds the in vitro autoradiography of [ Figure 7) . With regard to that, we assume that the constantly increasing uptake of activity in the cerebellum as a non-target region of a PDE2A radioligand, which is in contrast to the fast wash out of activity from the target region striatum, indicates specific binding of the structurally not analyzed radiometabolite [ 
Experimental Section
General Information
Chemicals were purchased from standard commercial sources in analytical grade and were used without further purification. Radio-/TLCs were performed on pre-coated silica gel plates (Alugram ® Xtra SIL G/UV254; Polygram ® SIL G/UV254, Roth, Karlsruhe, Germany). The compounds were localized at 254 nm (UV lamp) and/or by staining with aqueous KMnO4 solution or ninhydrin solution. Radio-TLC was recorded using a bioimaging analyzer system (BAS-1800 II, Fuji Photo Film, Co. Ltd., Tokyo, Japan) and images were evaluated with Aida 2.31 software (raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany). Column chromatography was conducted on silica gel (0.06-0.20 mm, Roth). HPLC separations were performed on JASCO systems equipped with UV detectors from JASCO and activity detectors from raytest Isotopenmessgeräte GmbH (GABI Star, Straubenhardt, Germany).
HPLC columns and conditions were: System A, semi-preparative HPLC (column: Reprosil-Pur C18-AQ, 250 × 10 mm, particle size: 10 µm; eluent: 50% MeCN/20 mM NH4OAcaq.; flow: 3 mL/min for [ 
Syntheses
The synthesis of the lead compound TA1 is already reported [38] and involves five steps, which were partly optimized. Furthermore, the patent does not provide NMR data of the published compounds 1-4 or TA1, which are reported herein. (1) [38] . To 4.02 g (1.6 eq.) 4-methylimidazole dissolved in CHCl3 (8 mL, instead of DMF [38] ) a solution of 4-(dimethylamino) pyridine (DMAP, 0.37 g, 10 mol %) in CHCl3 (2 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 10 min followed by the addition of triethylamine (TEA, 12.73 mL, 3 eq.; instead of solid KOH [38] ) and stirring at 0 °C for further 10 min. To this reaction mixture was added dropwise 2-chloro-6-methoxy-3-nitropyridine (5.77 g, 1 eq.) in CHCl3 (14 mL). After 30 min at 0 °C the mixture was stirred at ambient temperature overnight. The mixture was washed twice with water and aq. NaCl saturated solution (20 mL). The aqueous phase was extracted with CHCl3 (20 mL). The organic phase was dried over Na2SO4 and filtered. Evaporation of the solvent and subsequent purification by column chromatography (EtOAc/ n-hexane, 1:2, v/v) afforded 1 as a yellow solid (6.65 g, 93%). 1 (2) [38] . Compound 1 (6.62 g, 1 eq.) was dissolved in absolute EtOH (180 mL) and after addition of palladium on charcoal (0.20 g, 10%) in absolute EtOH (20 mL) the reaction mixture was hydrogenated under pressure (1.5-2 bar instead of 10 to 15 bar [38] ) at ambient temperature (instead of 40 °C [38] ). Afterwards the mixture was stirred overnight and filtered over kieselguhr (suspended in EtOH). The red brown filtrate was concentrated under reduced pressure and the residue was treated with cold methyl tert-butyl ether (MTBE, 20 mL). The mixture was stirred at 0 °C for 30 min and stored at 4 °C (fridge) overnight to precipitate the product. The light brown solid was filtered and dried in a desiccator under vacuum for two days. This procedure was repeated twice with the filtrate and the dry precipitates were combined to afford 4.54 g (79%) of 2. [5,1-c] pyrido [2,3-e] [1, 2, 4] triazine (3) [38] . Under ice bath cooling, compound 2 (100 mg, 1 eq.) was dissolved in CH3COOH (30 mL) followed by addition of aq. NaNO2 solution (51 mg, 1.5 eq. in 500 µL water) and water (2 mL). Precipitation of a yellow solid started immediately. The reaction mixture was stirred for 30 min (instead of 1-2 h [38] ) and the precipitate was filtered, washed with ethyl acetate and water, and dried in a desiccator under vacuum for three days (instead of re-crystallization from iso-propanol or column chromatography [38] ). 101 mg (96%) of 3 as a yellow solid were obtained. [5,1-c] pyrido [2,3-e] [1, 2, 4] triazine (4) [38] . A solution of compound 3 (0.74 g, 1 eq.; instead of 4-methoxy-7-methyl-imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine [38] ) in CH2Cl2 (50 mL; instead of MeCN [38] ) was stirred for 10 min under ice bath cooling. A suspension of N-bromosuccinimide (NBS, 0.92 g, 1.5 eq.) in CH2Cl2 (10 mL) was added dropwise and the round bottom flask was covered using aluminum foil. The reaction was stirred in an ice bath for 5 h and overnight at ambient temperature (instead of stirring at ambient temperature for 16 h [38] ). The mixture was washed once with aq. saturated solutions of Na2SO3, NaHCO3, and NaCl and water (20 mL each). The aqueous phase was extracted with CH2Cl2 (20 mL). The organic phase was dried over Na2SO4 and filtered. Evaporation of the solvent and subsequent purification by column chromatography (EtOAc/CH2Cl2, 1:6 to 1:4, v/v) afforded a yellow solid of 4 (0.74 g, 73%). [5,1-c] pyrido [2,3-e] [1, 2, 4] triazine (TA1) [38] . The synthesis of the lead compound TA1 was performed as described in the General Suzuki Coupling Procedure [38] . Subsequent evaporation of the solvent at 60 °C and purification by column chromatography (EtOAc/CH2Cl2, 1:6, v/v) afforded a yellow solid of TA1 (0.34 g, 81%).
6-Methoxy-2-(4-methyl-1H-imidazol-1-yl)-3-nitropyridine
6-Methoxy-2-(4-methyl-1H-imidazol-1-yl)pyridin-3-amine
2-Methoxy-7-methylimidazo
9-Bromo-2-methoxy-7-methylimidazo
9-(5-Butoxy-2-fluorophenyl)-2-methoxy-7-methylimidazo
The synthesis of various alkyl bis(4-methylbenzenesulfonates) is already reported [48] and was performed according to the literature. A solution of propane-1,3-diol or butane-1,4-diol (1 eq.) in CH2Cl2 (5 mL) was stirred at 0 °C (ice bath) for 10 min. The round bottom flask was covered using aluminium foil and 4 eq. of triethylamine (TEA) were added dropwise. Afterwards a solution of 4-methylbenzenesulfonyl chloride (2 eq.) in CH2Cl2 (10 mL) was added over a period of 15-30 min followed by the addition of 10 mol % of DMAP. The reaction mixture was stirred each for 1 h at 0 °C and at ambient temperature. The white precipitate (triethylamine hydrochloride) was filtered off. The light yellow filtrate was washed once with each 1 M HCl, aq. saturated solution of NaHCO3, water, and aq. saturated solution of NaCl. The aqueous phase was extracted once with CH2Cl2. The organic phase was dried over Na2SO4 and filtered. Evaporation of the solvent and subsequent purification by column chromatography (EtOAc/n-hexanes, 1:3 to 1:1, v/v) afforded a white solid (≥60% of each: propane-1,3-diyl bis(4-methylbenzenesulfonate) and butane-1,4-diyl bis(4-methyl-benzenesulfonate)), identified by 1 H-NMR.
General Procedure for the Preparation of Tosylate Precursors TA3a and TA4a
To a solution of compound TA1a (1 eq.) in MeCN (10 mL), K2CO3 (4 eq.) and the alkyl bis(4-methylbenzenesulfonate) (2 eq.) were added. The yellow suspension was stirred at 60-70 °C for 5 h and at ambient temperature overnight. In the case of an incomplete reaction (TLC) the mixture was heated to 60-70 °C for 5 h again and stirred at ambient temperature overnight. The mixture was filtered and the solvent was evaporated. The residue was resolved in CH2Cl2 (10 mL), washed with water (5 mL) and then with citric acid (5 mL, 25%). The aqueous phase was extracted with CH2Cl2 (2 mL). The combined organic phases were dried over Na2SO4, filtered and evaporation of the solvent yielded the crude tosylate precursors. [5,1-c] pyrido [2,3-e] [1, 2, 4] triazine-9-yl)phenoxy)propyl 4-methylbenzenesulfonate (TA3a) The procedure for tosylate precursors described above was performed with 170 mg of TA1a and 410 mg of propane-1,3-diyl bis(4-methylbenzenesulfonate), and afforded after column chromatography (EtOAc/CH2Cl2, 1:6 to 1:4, v/v) a yellow solid of TA3a (170 mg, 60%). 
3-(4-Fluoro-3-(2-methoxy-7-methylimidazo
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In Vitro PDE2A Affinity Assay
The inhibitory potencies of TA1-4 for human recombinant PDE2A and PDE10A proteins were determined by BioCrea GmbH (Radebeul, Germany) [38] . − cartridge (entry 1) in the remotely controlled synthesis module. The activity was eluted with an aqueous solution of K2CO3 (1.78 mg/0.4 mL water; entry 2), mixed with K2.2.2 (11.2 mg/1 mL MeCN; entry 3) into the reaction vessel (entry 6) and azeotropically dried for approximately 10 min. Thereafter, 1 mg of the tosylate TA3a dissolved in 1 mL MeCN (entry 4) was added, and the reaction mixture was stirred at 80 °C for 15 min. After cooling, the reaction mixture was diluted with 2 mL water (entry 5) and transferred into the injection vial. Semi-preparative HPLC (system A, entry 7) was performed for isolation of the desired radioligand [ Plus light cartridge (Waters; pre-conditioned with 20 mL of absolute EtOH and 60 mL water; entry 11), followed by washing with 2 mL water (entry 9) and elution of [ To obtain an injectable solution, the solvent was reduced under a gentle nitrogen stream at 70 °C and the radioligand was formulated in sterile isotonic saline containing 10% EtOH (v/v). Analytical radio-HPLC (system B, gradient and isocratic mode) of the final product spiked with the non-radioactive reference compound TA3 confirmed the identity of [ 
Determination of Lipophilicity (logD7.4) and in Vitro Stability
The lipophilicity of [ were investigated by incubation of the radioligands in phosphate buffered saline (PBS, pH 7.4), n-octanol and pig plasma at 37 °C for 60 min (~5 MBq of the radioligand added to 500 µL of each medium). Samples were taken at 15, 30 and 60 min after incubation and analyzed by radio-TLC and radio-HPLC (system B).
Animal Studies
All animal procedures were approved by the Animal Care and Use Committee of Saxony (TVV 08/13).
In Vitro Autoradiographic Studies in Rat Brain
Frozen sagittal brain sections obtained from female SPRD rats (10-12 weeks old) were thawed, dried in a stream of cold air, and preincubated for 20 min with incubation buffer (50 mM TRIS-HCl, pH 7.4, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 5 mM MgCl2) at ambient temperature. Brain sections were incubated with ~1 MBq/mL of [ The reconstruction parameters for the list mode data are: 3D-ordered subset expectation maximization (OSEM), 4 iterations, 6 subsets, energy window: 400-600 keV, coincidence mode: 1-5, ring difference: 81. The mice were positioned prone in a special mouse bed (heated up to 37 °C), with the head fixed to a mouth piece for the anesthetic gas supply with isoflurane in 40% air and 60% oxygen (anesthesia unit: U-410, agnthos, Lidingö, Sweden; Gas blender: MCQ, Rome, Italy). The PET data was collected by a continuous WB scan during the entire investigation. Following the 60 min PET scan a T1 weighted WB gradient echo sequence (GRE, TR = 20 ms; TE = 6.4 ms) was performed for AC and anatomical orientation. Image registration and evaluation of the region of interest (ROI) was done with ROVER (ABX advanced biochemical compounds, Radeberg, Germany).
The respective brain regions were identified using the MR information from the GRE scan. The activity data is expressed as mean standardized uptake value (SUV) of the overall ROI.
In Vivo Metabolism Studies in Mice
The radioligands [ (14,000× g, 1 min) , and brain homogenized in ~1 mL isotonic saline on ice (10 strokes of a PTFE plunge at 1000 rpm in a borosilicate glass cylinder; Potter S Homogenizer, B. Braun Melsungen AG, Melsungen, Germany).
Conventional Extraction Procedure
Twofold extractions of plasma (2 × 50 µL, 30 min p.i.) and brain samples (2 × 250 µL, 30 min p.i.) were performed using a mixture of ice-cold acetone/water (8:2, v/v; plasma or brain sample/organic solvent, 1:4, v/v). The samples were vortexed for 1 min, incubated on ice for 10 min (first extraction) or 5 min (second extraction) and centrifuged at 10,000 rpm for 5 min. Supernatants were collected and the precipitates were re-dissolved in ice-cold acetone/water for the second extraction. Aliquots from supernatants of each extraction step were taken. Activity thereof and of the precipitates was quantified using an automated gamma counter (1480 WIZARD, Fa. Perkin Elmer). The supernatants from both extractions were combined, concentrated under nitrogen stream at 70 °C and analyzed by radio-HPLC (system B).
Micellar Chromatography (MLC)
For preparation of the MLC injection samples, mouse plasma (20-50 µL, 30 min p.i.) was dissolved in 100-300 µL of 200 mM aqueous SDS and injected directly into the MLC system (500 µL sample loop; column: Reprosil-Pur C18-AQ, 250 × 4.6 mm, particle size: 10 µm; gradient: 0-15 min: 3% 1-PrOH, 15-40 min: 3% → 30% 1-PrOH; 40-49 min: 30% 1-PrOH, 49-50 min: 30% → 3% 1-PrOH; 50-60 min: 3% 1-PrOH/100 mM SDS, 10 mM Na2HPO4; flow: 1 mL/min; ambient temperature). Notably, a pre-column with 10 mm length was used and frequently exchanged to expand the life time of the RP-column. Homogenized brain material (100-200 µL, 30 min p.i.) was dissolved in 500 µL of 200 mM aqueous SDS, stirred at 75 °C for 5 min and after cooling to ambient temperature injected into the MLC system.
Conclusions
In conclusion, the novel radioligands [ Furthermore, compared to the conventional extraction procedure combined with analytical RP-HPLC, it could be shown that micellar HPLC is a more reliable method to quantify the amount of non-metabolized [ 
